Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Oculis Holding AG (NASDAQ:OCS) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $38.00.

Several equities research analysts recently commented on OCS shares. Robert W. Baird dropped their target price on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Guggenheim cut their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Needham & Company LLC cut their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently modified their holdings of OCS. China Universal Asset Management Co. Ltd. boosted its position in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of Oculis during the 1st quarter worth about $238,000. Millennium Management LLC acquired a new stake in shares of Oculis during the 4th quarter valued at about $312,000. Himension Capital Singapore PTE. LTD. acquired a new stake in shares of Oculis during the 1st quarter valued at about $503,000. Finally, Marshall Wace LLP bought a new stake in shares of Oculis in the 2nd quarter valued at approximately $393,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Price Performance

OCS opened at $13.09 on Monday. The firm has a market cap of $758.96 million, a price-to-earnings ratio of -7.52 and a beta of 0.51. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $12.42 and its 200 day moving average price is $21.27.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. The company had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, sell-side analysts expect that Oculis will post -2.01 earnings per share for the current year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.